aciclovir
Sezary Syndrome
Ohio State University Comprehensive Cancer CenterSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
25 Active assets in the Sezary Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Shanghai Jiao Tong University School of Medicine | Phase 4 | BB |
(+)-VINCRISTINE Shanghai Jiao Tong University School of Medicine | Phase 4 | BB |
PREDNISONE TABLETS Shanghai Jiao Tong University School of Medicine | Phase 4 | BB |
FILGRASTIM Eisai Inc. | Phase 4 | BB |
Inno-206 Eisai Inc. | Phase 4 | BB |
View all 43 →
Same molecule, other indications
aciclovir is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →